 Prometheus Biosciences NASDAQ: RXDX stock is rocketing higher on Wednesday after reporting results from its ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a studies of PRA023. PRA023 is a treatment in development for ulcerative colitis UC and Crohns disease CD . 